CR7797A - Preparacion solida - Google Patents

Preparacion solida

Info

Publication number
CR7797A
CR7797A CR7797A CR7797A CR7797A CR 7797 A CR7797 A CR 7797A CR 7797 A CR7797 A CR 7797A CR 7797 A CR7797 A CR 7797A CR 7797 A CR7797 A CR 7797A
Authority
CR
Costa Rica
Prior art keywords
solid preparation
preparation
active ingredient
insulin
except
Prior art date
Application number
CR7797A
Other languages
English (en)
Spanish (es)
Inventor
Koike Masahiko
Koyama Hiroyoshi
Hamaguchi Naoru
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32064024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7797(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR7797A publication Critical patent/CR7797A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CR7797A 2002-10-07 2005-04-19 Preparacion solida CR7797A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002294045 2002-10-07

Publications (1)

Publication Number Publication Date
CR7797A true CR7797A (es) 2005-11-15

Family

ID=32064024

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7797A CR7797A (es) 2002-10-07 2005-04-19 Preparacion solida

Country Status (25)

Country Link
US (1) US9101660B2 (https=)
EP (1) EP1561472B2 (https=)
JP (2) JP4236553B2 (https=)
KR (2) KR20070119095A (https=)
CN (1) CN100427143C (https=)
AU (1) AU2003271103B2 (https=)
BR (1) BR0315082A (https=)
CA (1) CA2501587C (https=)
CO (1) CO5700740A2 (https=)
CR (1) CR7797A (https=)
CY (1) CY1114863T1 (https=)
DK (1) DK1561472T3 (https=)
ES (1) ES2437072T5 (https=)
IL (1) IL167835A (https=)
MA (1) MA27487A1 (https=)
MX (1) MXPA05003668A (https=)
NO (1) NO332993B1 (https=)
NZ (2) NZ552559A (https=)
PL (1) PL219608B1 (https=)
PT (1) PT1561472E (https=)
RU (1) RU2357757C2 (https=)
SI (1) SI1561472T1 (https=)
UA (1) UA80991C2 (https=)
WO (1) WO2004030700A1 (https=)
ZA (1) ZA200503507B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
MXPA06004639A (es) 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
PL1878426T3 (pl) * 2005-04-26 2010-11-30 Sumitomo Dainippon Pharma Co Ltd Preparat w formie granulatu zawierający związek biguanidu
ZA200805147B (en) * 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation
KR101220643B1 (ko) * 2006-08-16 2013-01-14 알리코제약(주) 사포그릴레이트 함유 경구투여 형태의 약제
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
JP4832271B2 (ja) * 2006-12-11 2011-12-07 花王株式会社 粉末圧縮錠剤
CN101801351B (zh) * 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
US8563500B2 (en) 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
CN101417130B (zh) * 2007-10-22 2010-10-06 鲁南制药集团股份有限公司 一种治疗ⅱ型糖尿病及其并发症的药物组合物
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2010084504A2 (en) * 2008-05-26 2010-07-29 Sun Pharmaceutical Industries Ltd. A stable, oral solid dosage form
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
US8663661B2 (en) 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2465896C2 (ru) * 2011-01-20 2012-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция пролонгированного действия
CN105125539A (zh) * 2015-08-05 2015-12-09 浙江华海药业股份有限公司 吡格列酮二甲双胍片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
PT922464E (pt) * 1996-07-12 2005-07-29 Daiichi Seiyaku Co Materiais moldados por compressao rapidamente desintegraveis e processo para a sua producao
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
JPH1160476A (ja) 1997-08-25 1999-03-02 Taisho Pharmaceut Co Ltd 圧縮固形組成物
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ATE291418T1 (de) † 1998-07-28 2005-04-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
US6117451A (en) † 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
HK1040910B (en) † 1998-11-12 2009-06-26 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and metformin
IL143569A0 (en) 1998-12-24 2002-04-21 Metabasis Therapeutics Inc A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
WO2000066102A2 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AR030920A1 (es) † 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
JP2001335469A (ja) * 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
FR2812547B1 (fr) 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2002087965A (ja) * 2000-09-14 2002-03-27 Lion Corp 口中崩壊性アスピリン含有錠剤
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
CA2424770A1 (en) * 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
AU2003281181A1 (en) 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation

Also Published As

Publication number Publication date
PL376176A1 (en) 2005-12-27
MA27487A1 (fr) 2005-08-01
EP1561472B2 (en) 2021-01-20
AU2003271103B2 (en) 2008-02-28
ES2437072T3 (es) 2014-01-08
EP1561472A1 (en) 2005-08-10
AU2003271103A1 (en) 2004-04-23
CN1717253A (zh) 2006-01-04
RU2005113999A (ru) 2005-12-10
ZA200503507B (en) 2006-08-30
NO20052239D0 (no) 2005-05-06
KR20070119095A (ko) 2007-12-18
NO332993B1 (no) 2013-02-11
CN100427143C (zh) 2008-10-22
IL167835A (en) 2010-11-30
WO2004030700A1 (ja) 2004-04-15
DK1561472T3 (da) 2013-11-11
BR0315082A (pt) 2005-08-16
US9101660B2 (en) 2015-08-11
PL219608B1 (pl) 2015-06-30
CO5700740A2 (es) 2006-11-30
CA2501587A1 (en) 2004-04-15
NZ539711A (en) 2007-09-28
JP2004149521A (ja) 2004-05-27
HK1080385A1 (en) 2006-04-28
EP1561472A4 (en) 2009-07-08
JP4236553B2 (ja) 2009-03-11
EP1561472B1 (en) 2013-10-02
MXPA05003668A (es) 2005-06-08
CA2501587C (en) 2008-06-03
KR20050070039A (ko) 2005-07-05
NO20052239L (no) 2005-06-29
KR100820609B1 (ko) 2008-04-10
RU2357757C2 (ru) 2009-06-10
PT1561472E (pt) 2013-12-09
US20050287207A1 (en) 2005-12-29
UA80991C2 (en) 2007-11-26
JP2008208141A (ja) 2008-09-11
NZ552559A (en) 2008-04-30
CY1114863T1 (el) 2016-12-14
SI1561472T1 (sl) 2014-01-31
ES2437072T5 (es) 2021-10-13

Similar Documents

Publication Publication Date Title
CR7797A (es) Preparacion solida
CR10992A (es) Preparacion solida que comprende alogliptina y pioglitazona
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
WO2006037948A3 (en) Methods and kits for delivering drugs by nebulisation
ECSP12012056A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
AR054689A1 (es) Mecanismo de visualizacion de dosis para un dispositivo para la administracion de farmacos
BRPI0606397B8 (pt) derivados de 1-tio-d-glucitol, método para produzir os mesmos e produto farmacêutico que os contém.
AR070842A1 (es) Regimen de dosificacion para un agonista de receptor selectivo de s1p1
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
MX2009011900A (es) Curacion de herida diabetica.
CO2024002748A2 (es) Profármaco de derivados de pirrolidona como activador de glucocinasa
CL2008003024A1 (es) Compuestos derivados de alquilsulfonilbenzotiazol, moduladores del receptor de grelina; formulacion farmaceutica; y uso para el tratamiento de obesidad o sobrepeso, diabetes, sindrome metabolico, entre otras.
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
TW200722420A (en) Propane-1,3-dion derivative or salt thereof
PE20051156A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
PE20210367A1 (es) Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina